Showing 8441-8450 of 9130 results for "".
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte
- Can Topical Fluorouracil Prevent Keratinocyte Carcinoma?https://practicaldermatology.com/news/can-topical-fluorouracil-prevent-keratinocyte-carcinoma/2457935/A recent study published in JAMA Dermatology found that a conventional course of fluorouracil to the face and ears substantially reduces surgery for squamous cell carcinoma for 1 year without significantly
- Jiangsu Hengrui Medicine and Arcutis Partner for Immune-Mediated Dermatology Therapy Using SHR0302https://practicaldermatology.com/news/jiangsu-hengrui-medicine-and-arcutis-partner-for-immune-mediated-dermatology-therapy-using-shr0302/2457936/Jiangsu Hengrui Medicine Co., Ltd., a fully integrated biopharmaceutical company based in Shanghai, and Arcutis, Inc., a biotechnology company based in Menlo Park, CA, entered into an exclusive option and license agreement for the development and commercialization of topical applications of Hengr
- BridgeBio Pharma Appoints Drs. Sanuj Ravindran and Eric Michael David as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programshttps://practicaldermatology.com/news/bridgebio-pharma-appoints-drs-sanuj-ravindran-and-eric-michael-david-as-ceos-in-residence-to-lead-dermatology-and-gene-therapy-programs/2457942/BridgeBio Pharma, a clinical-stage biopharmaceutical company, today announced that it has strengthened its executive leadership team with two key hires who will join the company as CEOs-in-residence. Sanuj Ravindran, MD, will serve as CEO of PellePharm, Inc. and wil
- UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-bimekizumab-shows-joint-and-skin-responses-in-psoriatic-arthritis/2457945/UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psor
- Harnessing the Power of Social Media: One Viral Post Can Generate Tons of Skin Cancer Awarenesshttps://practicaldermatology.com/news/harnessing-the-power-of-social-media-one-viral-post-can-generate-tons-of-skin-cancer-awareness/2457953/You don’t have to be a celebrity to give voice to a public health concern on social media. Just one person can generate awareness about skin cancer -- when his or her post and picture is shared thousands of times on Facebook, researchers report in the journal Preventive Medicine
- Psoriasis Severity Linked to Diabetes Riskhttps://practicaldermatology.com/news/psoriasis-severity-linked-to-diabetes-risk/2457970/Psoriasis patients are more likely to develop Type 2 diabetes than their psoriasis-free counterparts, and this risk increases dramatically based on the severity of the disease, according to researchers from the Perelman School of Medicine at the University of
- Promius Pharma Employees Fundraise for Hurricane Victimshttps://practicaldermatology.com/news/promius-pharma-employees-fundraise-for-hurricane-victims/2457974/Promius Pharma LLC's employees raised $12,715 to support American Red Cross relief efforts to assist those affected by the recent hurricanes. Additionally, Promius' parent company Dr. Reddy's Laboratories matched this donation for a combined contribution
- Long-Term Use of Lilly's Taltz Shows Efficacy Improvements in PsA for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitorshttps://practicaldermatology.com/news/long-term-use-of-lillys-taltz-shows-efficacy-improvements-in-psa-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors/2457980/Patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or had inadequate responses to TNF inhibitors, showed improvements in the signs and symptoms of PsA across treatment groups for up to 52 weeks, according to Eli Lilly and Company. Interi
- DermTech Adds Dr. Harold Rabinovitz to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-harold-rabinovitz-to-scientific-advisory-board/2457982/DermTech, Inc., appointed Harold Rabinovitz, MD to its Scientific Advisory Board. Dr. Rabinovitz is a Board Certified Dermatologist and a voluntary Clinical Professor of Dermatology at University of Miami School of Medicine. He is world-renown for his work in dermoscopy and confocal microscopy.</